GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Oruka Therapeutics ORKA · USD

Health Care · US listing · 🇺🇸 United States

Compare

104.56

+1.65%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Oruka Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Oruka Therapeutics is based in Menlo Park, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ORKA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2023, it reported revenue of $0.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
21 Jul 2000
Employees
11
Website
arcabio.com ↗
Head office
855 OAK GROVE AVE., MENLO PARK, CA, 94025
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Dr. Samarth KulkarniNon-Executive Independent Chairman of the Board$27,740
  • Dr. Lawrence KleinPresident, Chief Executive Officer, Director, since 2024$520,911
  • Ms. Laura SandlerChief Operating Officer
  • Mr. Arjun AgarwalSenior Vice President - Finance, Treasurer
  • Mr. Paul QuinlanGeneral Counsel, Secretary$310,445
  • Dr. Joana GoncalvesChief Medical Officer$317,986
  • Ms. Kristine BallIndependent Director$20,548
  • Mr. Carl DambkowskiIndependent Director$16,267
  • Mr. Peter HarwinIndependent Director$19,178
  • Dr. Cameron TurtleIndependent Director$20,377
  • Mr. Alan LadaIR Contact Officer, since 2024

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Oruka Therapeutics Inc develops genetically targeted therapies for heart failure in the Health Care sector.
  • Oruka Therapeutics Inc's lead product Gencaro is in Phase IIB/III clinical trial for atrial fibrillation treatment.
  • Oruka Therapeutics Inc has 11 full-time employees focused on cardiovascular disease research.

Weaknesses

  • Oruka Therapeutics Inc has only 11 employees in the Biotechnology industry.
  • Oruka Therapeutics Inc's business is limited to cardiovascular disease therapies.
  • Oruka Therapeutics Inc's lead product Gencaro is still in clinical trials.

Opportunities

  • Oruka Therapeutics Inc could expand its cardiovascular disease therapies to new markets.
  • Oruka Therapeutics Inc may benefit from increased focus on heart failure treatments.
  • Oruka Therapeutics Inc could leverage its Phase IIB/III clinical trial results for future growth.

Threats

  • Oruka Therapeutics Inc faces competition from other biopharmaceutical companies in the Health Care sector.
  • Oruka Therapeutics Inc's clinical trial results could be negative for Gencaro.
  • Oruka Therapeutics Inc's business is dependent on the success of Gencaro in clinical trials.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.